Drawing based on the label description. No photo yet.
“Dapagliflozin and metformin HCl extended-release tablets are available as follows: Dapagliflozin and metformin HCl extended-release tablets 5/500 mg:Orange colored oval shaped, beveled edge, biconvex, film-coated tablets debossed with "DM1" on one face and plain on other face”
DM1 pill
Pill with imprint DM1 is orange, oval, 17 mm and has been identified as Dapagliflozin and Metformin Hydrochloride 5 mg / 500 mg. It is used for type 2 diabetes and heart failure. It is supplied by Micro Labs Limited.
Dapagliflozin and Metformin Hydrochloride 5 mg / 500 mg
- Imprint
- DM1
- Strength
- Dapagliflozin 5 mg / Metformin Hydrochloride 500 mg
- Used for
- Type 2 diabetes and heart failure
- Color
- Orange
- Shape
- Oval
- Size
- 17 mm
- Score
- No score line
- Form
- Tablet, film coated, extended release
- Manufacturer
- Micro Labs Limited
- Drug class
- Diabetes medicine (SGLT2 inhibitor)
- NDC
- 42571-320, 42571-320-30, 42571-320-90, 42571-320-05
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Dapagliflozin and Metformin used for?
Dapagliflozin and Metformin is used for type 2 diabetes and heart failure.
- Medicine type
- Diabetes medicine (SGLT2 inhibitor); diabetes medicine (biguanide)
Official uses from the US prescribing label
Dapagliflozin and metformin hydrochloride extended-release tablets are a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin, when used as a component of dapagliflozin and metformin hydrochloride extended-release tablets, is indicated in adults with type 2 diabetes mellitus to reduce the risk of:
- Sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression.
- CV death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure.
- Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.
Limitations of Use
- Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
- Because of the metformin hydrochloride component, the use of dapagliflozin and metformin hydrochloride extended-release tablets is limited to patients with type 2 diabetes mellitus for all indications.
- Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. Dapagliflozin and metformin hydrochloride extended-release tablets are not expected to be effective in these populations.
Pediatric use information is approved for AstraZeneca AB’s Xigduo ® XR (dapagliflozin and metformin hydrochloride) Extended-Release Tablets. However, due to AstraZeneca AB’s marketing exclusivity rights, this drug product is not labeled with that information.
From the FDA-approved label on DailyMed (published Sep 24, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows DM1 and the other side is plain.
- It is orange, oval, 17 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Dapagliflozin, Metformin Hydrochloride
Inactive: Cellulose, Microcrystalline, Anhydrous Lactose, Crospovidone, Polysorbate 80, Silicon Dioxide, Magnesium Stearate, Ferric Oxide Yellow, Povidone K30, Hypromellose, Unspecified, Glyceryl Dibehenate, Talc, Polyethylene Glycol, Unspecified, Titanium Dioxide, Fd&c Yellow No. 6, Polyvinyl Alcohol, Unspecified
Other pills with imprint DM1
Same imprint, different listing. Check the color, size and maker against your pill.
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
RZ1
Ranolazine 500 mg
Orange, oval, 17 mm
Used for chest pain (angina)
-
AC13
Darunavir 600 mg
Orange, oval, 18 mm
Used for HIV
-
93 1122
Etodolac 400 mg
Orange, oval, 18 mm
Used for pain and rheumatoid arthritis
- WWV 50 Crinecerfont 50 mg Orange, oval, 16 mm Used for congenital adrenal hyperplasia
- 150 Nirogacestat 150 mg Orange, oval, 18 mm Used for desmoid tumors
- LT750 Levetiracetam 750 mg Orange, oval, 18 mm Used for focal seizures and tonic-clonic seizures
Other Dapagliflozin and Metformin pills
- 1073 10 1000 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- N 25 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- D M 10 1000 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- MD4 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Brown, oval, 20 mm Used for type 2 diabetes and heart failure
- RL 61 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- L111 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- F26 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- DM4 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 21 mm Used for type 2 diabetes and heart failure